144 related articles for article (PubMed ID: 31730343)
1. Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.
Wei J; Hu J; Wang L; Xie L; Jin MS; Chen X; Liu J; Jin J
J Med Chem; 2019 Dec; 62(23):10897-10911. PubMed ID: 31730343
[TBL] [Abstract][Full Text] [Related]
2. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
4. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
[TBL] [Abstract][Full Text] [Related]
5. Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD.
Kurian N; Cohen TS; Öberg L; De Zan E; Skogberg G; Vollmer S; Baturcam E; Svanberg P; Bonn B; Smith PD; Vaarala O; Cunoosamy DM
Int J Chron Obstruct Pulmon Dis; 2019; 14():2611-2624. PubMed ID: 32063702
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
Van Dort ME; Hong H; Wang H; Nino CA; Lombardi RL; Blanks AE; Galbán S; Ross BD
J Med Chem; 2016 Mar; 59(6):2512-22. PubMed ID: 26943489
[TBL] [Abstract][Full Text] [Related]
7. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models.
Chiacchiera F; Grossi V; Cappellari M; Peserico A; Simonatto M; Germani A; Russo S; Moyer MP; Resta N; Murzilli S; Simone C
Cancer Lett; 2012 Nov; 324(1):98-108. PubMed ID: 22579651
[TBL] [Abstract][Full Text] [Related]
8. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
[TBL] [Abstract][Full Text] [Related]
9. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Kwon OS; Hong SK; Kwon SJ; Go YH; Oh E; Cha HJ
Cancer Lett; 2017 Sep; 403():48-58. PubMed ID: 28606806
[TBL] [Abstract][Full Text] [Related]
10. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
[TBL] [Abstract][Full Text] [Related]
11. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
Nan XY; Wu Y; Zhang LH; Yang ZJ
Yao Xue Xue Bao; 2016 Oct; 51(10):1551-7. PubMed ID: 29932599
[TBL] [Abstract][Full Text] [Related]
13. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.
Li X; Hou J; Wang C; Liu X; He H; Xu P; Yang Z; Chen Z; Wu Y; Zhang L
Molecules; 2013 Nov; 18(11):13957-78. PubMed ID: 24225774
[TBL] [Abstract][Full Text] [Related]
15. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2.
Zheng CF; Guan KL
J Biol Chem; 1993 May; 268(15):11435-9. PubMed ID: 8388392
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
19. Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.
Meloche S; Gopalbhai K; Beatty BG; Scherer SW; Pellerin J
Cytogenet Cell Genet; 2000; 88(3-4):249-52. PubMed ID: 10828601
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
